Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
Abstract Background Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the A...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-03-01
|
Series: | Surgical Case Reports |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40792-018-0430-7 |